Literature DB >> 9314035

Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery.

M D Randall1, A I McCulloch, D A Kendall.   

Abstract

We have recently proposed that anandamide, or a related cannabinoid, is the endothelium-derived hyperpolarizing factor (EDHF) and have now compared EDHF-mediated responses (induced by carbachol in the presence of both nitric oxide and prostanoid synthesis inhibitors) with those induced by anandamide in the rat isolated superior mesenteric arterial bed. Both EDHF-mediated and anandamide-induced relaxations were inhibited in the presence of high K+ (60 mM) and opposed by blockade of K+ channels with 10 mM tetraethylammonium. The cytochrome P450 inhibitors, and putative EDHF inhibitors, clotrimazole (10 microM) and proadifen (SKF 525A) (10 microM), opposed both anandamide-induced and EDHF-mediated relaxations and also relaxant responses to the K+ channel activator levcromakalim. Therefore, EDHF-mediated and anandamide-induced vasorelaxations show very similar pharmacological characteristics, with both responses being mediated via K+ channel activation. Further, the actions of EDHF and anandamide are both sensitive to proadifen and clotrimazole, EDHF antagonists which appear to act through K+ channel inhibition. Accordingly, these results support our proposal that an endocannabinoid is an EDHF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314035     DOI: 10.1016/s0014-2999(97)01137-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors.

Authors:  M Domenicali; J Ros; G Fernández-Varo; P Cejudo-Martín; M Crespo; M Morales-Ruiz; A M Briones; J-M Campistol; V Arroyo; E Vila; J Rodés; W Jiménez
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 2.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

3.  Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors.

Authors:  L Moezi; S A Gaskari; H Liu; S K Baik; A R Dehpour; S S Lee
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

4.  Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels.

Authors:  J Grainger; G Boachie-Ansah
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

5.  Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Identification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the rat.

Authors:  S J Stanford; J M Gitlin; J A Mitchell
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

7.  The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication.

Authors:  A T Chaytor; P E Martin; W H Evans; M D Randall; T M Griffith
Journal:  J Physiol       Date:  1999-10-15       Impact factor: 5.182

8.  Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed.

Authors:  David Harris; Audrey I McCulloch; David A Kendall; Michael D Randall
Journal:  J Physiol       Date:  2002-03-15       Impact factor: 5.182

9.  Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries.

Authors:  Varadarajan Sudhahar; Sean Shaw; John D Imig
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

10.  Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels.

Authors:  Maria Rosaria Romano; Marcello D Lograno
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.